去纤维钠去哪能买到？

Defibrotide is a mixture of sodium salts of single-stranded deoxyoligonucleotides produced from porcine intestinal mucosal genomic DNA through controlled depolymerization. Defibrotide sodium is an adenosine receptor agonist with multiple effects. The adenosine A1/A2 receptors of endothelial cells are involved in the regulation of endothelial cells and the response of endothelial cells to injury. Defibrotide sodium can act on these receptors to produce a variety of downstream effects. On March 30, 2016, Defibrotide was approved by the US FDA for the treatment of severe hepatic veno-occlusive disease in adults and children after hematopoietic stem cell transplantation (usually complicated by renal and pulmonary function abnormalities). This is the first drug approved by the FDA for the treatment of severe hepatic veno-occlusive disease. In vitro, Defibrotide increases tissue plasminogen activator (t-PA) and thrombomodulin expression and decreases von Willebrand factor (vWF) and plasminogen activator inhibitor-1 (PAI-1) expression, thereby reducing EC activation and increasing EC-mediated fibrinolysis. Defibrotide protects ECs from chemotherapy, tumor necrosis factor-alpha (TNF-alpha), serum starvation, and perfusion-induced injury. 

Where can I buy fiber-reduced sodium? It is understood that Defibrotide, produced by Irish Jazz Pharmaceuticals, has a specification of 200mg and a price of about $21,600. Due to the floating exchange rate, the price is not fixed. If patients want to know the specific price information of this drug, or if they want to purchase the cost-effective Defibrotide overseas, they can consult with domestic reliable overseas medical service companies (such as Medical Travel).

Recommended dose of Defibrotide: 6.25 mg/kg given as a 2-hour intravenous infusion every 6 hours. The dose should be based on the patient's baseline weight, which is defined as the patient's weight before the HSCT preparation protocol. Defibrotide was administered for a minimum of 21 days. If signs and symptoms of hepatic venule occlusion do not resolve after 21 days, continue Defibrotide until resolution of hepatic venule occlusion or up to a maximum of 60 days. 

Patients should note: Before administration of Defibrotide, confirm that the patient is not experiencing clinically significant bleeding and is hemodynamically stable on no more than one vasopressor. Do not coadminister Defibrotide with other intravenous medications at the same time and in the same intravenous line. If a serious or life-threatening allergic reaction occurs, discontinue Defibrotide, treat with standard medical care, and monitor until signs and symptoms resolve. Contraindications: Concomitant administration with systemic anticoagulants or fibrinolytic therapy. Known hypersensitivity to Defibrotide or to any of the excipients. 

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician. 

Recommended related articles: